A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595Phase 3Active, not recruiting
- Lead sponsor
- Definium Therapeutics US, Inc. (Industry)
- Enrollment
- 245 (actual)
- Start date
- 29 Jan 2025
- Primary completion
- 13 Aug 2026 (actual)
- Study completion
- 1 May 2027
- Last update posted
- 4 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Triple
- Arms
- 3
Interventions
- Placebo Other
- DT120 Drug
Conditions and primary outcome
- Generalized Anxiety Disorder
Primary outcome
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12 (Baseline to Week 12)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedPsychedelic medicine: mechanisms, evidence, and translation to practice.
BMJ (Clinical research ed.) · 2026 Feb 23
PubMed 41730563 (opens in a new tab)DOI 10.1136/bmj-2024-081723 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06809595 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.